David Cunningham

机构：Royal Marsden NHS Foundation Trust, Royal Marsden Hospital · ORCID：0000-0001-5158-1069

发表论文 2043 篇 · 总被引 133154 次 · h-index 153

代表论文

• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 55)
• Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer (2025 · Journal of Clinical Oncology · 被引 47)
• Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial (2025 · The Lancet Haematology · 被引 16)
• Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis (2025 · Journal of Clinical Oncology · 被引 14)
• Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial (2025 · The Lancet Oncology · 被引 12)
• Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial (2026 · Journal of Clinical Oncology · 被引 6)